+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Beyondspring S Rationale For The Plinabulin Neulasta Combination For Neutropenia Prevention Accepted As Abstracts At 2019 Asco Annual Meeting is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Beyondspring S Rationale For The Plinabulin Neulasta Combination For Neutropenia Prevention Accepted As Abstracts At 2019 Asco Annual Meeting | RobinsPost News & Noticias

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results


BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies- SITC 2023 ... Read More

BeyondSpring Files 2023 Annual Report on Form 20-F


The annual report ... lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. BeyondSpring’s pipeline also includes ... Read More

Forbes Press Releases


In this section, you’ll find the latest Forbes press ... annual ForbesBLK Summit, taking place in Atlanta and virtually on June 23-25, 2024. The collective net worth of Korea’s 50 Richest ... Read More

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting


full-length multispecific antibodies (Biclonics ® and Triclonics ®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO ... Read More

Press Release Portal


Does your organization or business have an announcement to promote? The Marietta Daily Journal's self-service Press Release Portal can get your organization's announcement the placement it needs. Read More

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting


We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ... Read More

Bizspotlight: Multi-Channel Press Release in Chicago Business Journal


Highlight and promote your company’s news with a fresh approach to press release distribution in Chicago. BizSpotlight provides your company exposure to a targeted audience of local Business ... Read More

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results


BeyondSpring ... Plinabulin’s ability to reduce infectious neutropenic fever for multiple myeloma patients undergoing Autologous Hematopoietic Stem Cell Transplantation (AHCT), at the ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus